ALR TECHNOLOGIES INC. (OTCMKTS:ALRT) Files An 8-K Regulation FD DisclosureITEM 7.01REGULATION FD DISCLOSURE.
510(K) Clearance
On September 19, 2017 the Company announced that it has received 510(k) clearance from the United States Food and Drug Administration for its insulin dose adjustment feature of the ALR Technologies Inc. Diabetes Managements System (also referred to as the “ALR Health-e-Connect System”).
Deficient Reporting Status
The Company has received notice from the Securities and Exchange Commission (the “SEC”) that the Company is not in compliance with its reporting requirements under the Securities Exchange Act (the “Act”). If the Company does not file all required reports, the Company may be subject to an administrative proceeding to revoke its registration under the Act. The notice also stated that the Company stock may be subject to a trading suspension by the SEC to the Act. At this time, the Company does not have the resources to file all required reports to bring the Company into compliance, and to continue filing the required reports to maintain compliance.
ITEM 9.01EXHIBITS AND FINANCIAL STATEMENTS.
| Exhibit | Document Description |
| 99.1 | Press Release. |
ALR TECHNOLOGIES INC. Exhibit…To view the full exhibit click here
About ALR TECHNOLOGIES INC. (OTCMKTS:ALRT)
ALR Technologies Inc. is a medical device company. The Company is engaged in providing remote monitoring and care facilitation for patients with diabetes. The Company focuses on commercializing its Heath-e-Connect System. The Company has developed a compliance monitoring system that will allow healthcare professionals to remotely monitor patient health conditions and provide patient health management. The Company’s products utilize Internet-based technologies to facilitate healthcare provider’s ability to monitor their patient’s health and ensure adherence to health maintenance activities. The Company’s Diabetes Care Facilitators and Health Data Monitors will track that data and based on clinician-approved protocols, will facilitate care interventions when patients show blood glucose readings that are out of an acceptable range or if they are failing to test their blood glucose as prescribed.